MediciNova (MNOV) Stock Analysis & AI Equity Report
MediciNova (MNOV) overview
MediciNova (MNOV) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 0.4m and operating profit of USD -13.3m; the year-end share price was 1.31 USD and market capitalisation was USD 64.5m. MediciNova is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get MediciNova's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About MediciNova
MediciNova is a biopharmaceutical company developing therapeutics for serious diseases with unmet medical needs, with a commercial focus on the United States. Its development activities center on MN-166 (ibudilast) for neurological and other disorders, including multiple sclerosis and ALS, and MN-001 (tipelukast) for fibrotic and metabolic disorders, including nonalcoholic fatty liver disease and hypertriglyceridemia.
Generate the MediciNova report
MediciNova is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for MediciNova and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on MediciNova
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.